Objective: Bipolar disorder (BD) is challenging to treat, and fewer treatments are available for depressive episodes compared to mania. Light therapy is an evidence-based nonpharmacological treatment for seasonal and nonseasonal major depression, but fewer studies have examined its efficacy for patients with BD. Hence, we reviewed the evidence for adjunctive light therapy as a treatment for bipolar depression.

Methods: We conducted a systematic review of databases from inception to June 30, 2019, for randomized, double-blind, placebo-controlled trials of light therapy in patients with BD (CRD42019128996). The primary outcome was change in clinician-rated depressive symptom score; secondary outcomes included clinical response, remission, acceptability, and treatment-emergent mood switches. We quantitatively pooled outcomes using meta-analysis with random-effects models.

Results: We identified seven trials representing 259 patients with BD. Light therapy was associated with a significant improvement in Hamilton Depression Rating Scale score (standardized mean difference = 0.43, 95% confidence interval [CI], 0.04 to 0.82, = 0.03). There was also a significant difference in favor of light therapy for clinical response (odds ratio [] = 2.32; 95% CI, 1.12 to 4.81; = 0.024) but not for remission. There was no difference in affective switches between active light and control conditions ( = 1.30; 95% CI, 0.38 to 4.44; = 0.67). Study limitations included different light treatment parameters, small sample sizes, short treatment durations, and variable quality across trials.

Conclusion: There is positive but nonconclusive evidence that adjunctive light therapy reduces symptoms of bipolar depression and increases clinical response. Light therapy is well tolerated with no increased risk of affective switch.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265610PMC
http://dx.doi.org/10.1177/0706743719892471DOI Listing

Publication Analysis

Top Keywords

light therapy
32
clinical response
12
light
10
therapy patients
8
bipolar depression
8
systematic review
8
evidence adjunctive
8
adjunctive light
8
therapy
7
patients
4

Similar Publications

Laryngocutaneous fistula is one of the most important complications encountered after larynx surgery. Stem cell therapy is a promising treatment approach for the future, both without the need for surgical methods and by assisting surgical methods to close the fistula. 30 female Downey Sprague rats were divided into 5 separate groups and pharyngocutaneous fistula was created.

View Article and Find Full Text PDF

Gliomas are aggressive intracranial tumors of the central nervous system with a poor prognosis, high risk of recurrence, and low survival rates. Radiation, surgery, and chemotherapy are traditional cancer therapies. It is very challenging to accurately image and differentiate the malignancy grade of gliomas due to their heterogeneous and infiltrating nature and the obstruction of the blood-brain barrier.

View Article and Find Full Text PDF

Integration of Motion and Stillness: A Paradigm Shift in Constructing Nearly Planar NIR-II AIEgen with Ultrahigh Molar Absorptivity and Photothermal Effect for Multimodal Phototheranostics.

J Am Chem Soc

January 2025

Department of Chemistry, The Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Division of Life Science, State Key Laboratory of Molecular Neuroscience, and Department of Chemical & Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong 999077, China.

The two contradictory entities in nature often follow the principle of unity of opposites, leading to optimal overall performance. Particularly, aggregation-induced emission luminogens (AIEgens) with donor-acceptor (D-A) structures exhibit tunable optical properties and versatile functionalities, offering significant potential to revolutionize cancer treatment. However, trapped by low molar absorptivity (ε) owing to the distorted configurations, the ceilings of their photon-harvesting capability and the corresponding phototheranostic performance still fall short.

View Article and Find Full Text PDF

[Diabetology : what's new in 2024].

Rev Med Suisse

January 2025

Service d'endocrinologie et diabétologie, Hôpitaux universitaires de Genève, 1211 Genève 14.

Diabetology is a continuously evolving discipline, many molecules are developed, and treatment recommendations change regularly according to the latest published studies. After lifestyle measures that must always be preferred before any drug, metformin remains the pharmacological basis of treatment. Current recommendations favor the introduction of an SGLT2 inhibitor or a GLP-1 receptor agonist after metformin because these molecules have shown beneficial cardiovascular and renal effects.

View Article and Find Full Text PDF

Potential of Type II NADH-Dehydrogenase in Antitubercular Drug Discovery.

ACS Infect Dis

January 2025

Department of Pharmaceutical Engg.Tech, IIT-Banaras Hindu University,Varanasi, Uttar Pradesh 221005, India.

The type II NADH-dehydrogenase enzyme in plays a critical role in the efficient functioning of the oxidative phosphorylation pathway. It acts as the entry point for electrons in the electron transport chain, which is essential for fulfilling the energy requirements of both replicating and nonreplicating mycobacterial species. Due to the absence of the type II NADH-dehydrogenase enzyme in mammalian mitochondria, targeting the type II NADH-dehydrogenase enzyme for antitubercular drug discovery could be a vigilant approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!